621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner

Matthew Henn; Christopher Ford; Edward O’Brien; Jennifer Wortman; Liyang Diao; Christopher Desjardins; Amelia Tomlinson; Kevin Litcofsky; Mark Wilcox; Anthony Buckley; Patricia Bernardo; Barbara McGovern; John G Aunins; David N Cook; Michele Trucksis

Journal ArticleOPEN ACCESS

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner

Henn M
Ford C
O’Brien E
et al.

Open Forum Infectious Diseases (2018) 5(suppl_1) S226-S227

DOI: 10.1093/ofid/ofy210.628

N/ACitations

6Readers

Abstract

AbstractBackground. C. difficile recurs when dormant spores germinate in the dysbiotic gut, facilitated by an increase of 1° vs. 2° bile acids. SER-109, an eco

Cite

CITATION STYLE

APA

Henn, M., Ford, C., O’Brien, E., Wortman, J., Diao, L., Desjardins, C., … Trucksis, M. (2018). 621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner. Open Forum Infectious Diseases, 5(suppl_1), S226–S227. https://doi.org/10.1093/ofid/ofy210.628

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner

Abstract

Cite

Register to see more suggestions